Intrathecal opioids for the treatment of refractory pain syndromes
DOI:
https://doi.org/10.47924/neurotarget2009314Keywords:
catheter, Chronic hiccups, drug, implantation, intrathecal, metabolism, Morphine, neurosurgery, pain, pumpAbstract
For more than 20 years intrathecal opioid application with implantable pumps is an option for selected patients with malignant as well as non-malignant pain. In general, most types of pain should be treatable by opioid medication. However, the associated systemic side-effects such as nausea, vomiting, constipation or the risk of depression of the central nervous system hinder the application of oral or intravenous opioid therapy as a sole, widely applicable treatment. Causes of non-malignant pain that may represent an indication for intrathecal drug-delivery systems include: failed back syndrome, neuropathic pain, axial spinal pain, complex regional pain syndrome, diffuse pain, brachial plexitis, central pain, failed spinal cord stimulation (SCS) therapy, arachnoiditis, poststroke pain, spinal cord injury pain and peripheral neuropathy. Due to the proximity to the receptor sites, the therapeutic effect of intrathecal drug application lasts longer and the rate of systemic side effects is reduced. Before definitive pump implantation, the therapeutic effect of intrathecal opioid therapy is tested with an external pump. If there is no clear and satisfactory effect in this trial application, pump implantation is not indicated. In our patients, with a follow-up exceeding 3 years, the reduction of non-malignant pain (assessed with the Visual Analogue Scale, VAS) was good or excellent (pain decrease >50%) in 71.3% of the patients, fair (VAS 5-6) in 19.8% and poor (VAS 7-10) in 8.9%. After 3 years of continuous treatment, we observed catheter-related technical problems (catheter dislocation, obstruction, kinking, disconnection or rupture) in 17 of 165 patients. Pump malfunctions were very rare (8 of 165 cases) and limited to older pump types. Reversible, specific drug-related side effects of long-term therapy with intrathecal pumps developed in 32 of the 165 patients. In our series, the mean serum/cerebrospinal fluid (CSF) concentration ratio for morphine was 1/3000, which explains the low rate of systemic side effects. Local diffusion difficulties in CSF cause an uneven distribution of morphine in CSF. Therefore the clinical effect is markedly influenced by the position of the catheter tip, a fact that should be kept in mind during catheter implantation. Intrathecal drug application is cost effective and can significantly improve the quality of life in selected patients. An intensive training in this method and awareness of its specific complications is necessary for everyone to participate in the consulting and implanting team. Pumps for chronic intrathecal opioid application should only be implanted in specialized centers.
Metrics
References
Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999;44(2):289-300.
Adriaensen H. Opioid drugs in chronic non-malignant pain? Acta Anaesthesiol Belg 1988;39(3 Suppl 2):67-70.
Aldrete JA. Extended epidural catheter infusions with analgesics for patients with noncancer pain at their homes. Reg Anesth 1997;22(1):35-42.
Angel IF, Gould HJ Jr, Carey ME. Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin. Surg Neurol 1998;49(1):92-8.
Bedder MD. Epidural opioid therapy for chronic nonmalignant pain: critique of current experience. J Pain Symptom Manage 1996;11(6):353-6.
Bernards CM, Kopacz DJ, Michel MZ. Effect of needle puncture on morphine and lidocaine flux through the spinal meninges of the monkey in vitro. Implications for combined spinal-epidural anesthesia. Anesthesiology 1994;80(4):853-8.
Chambers FA, MacSullivan R. Intrathecal morphine in the treatment of chronic intractable pain. Ir J Med Sci 1994;163(7):318-21.
Dahm P, Nitescu P, Appelgren L, Curelaru I. Efficacy and technical complications of long-term continuous intraspinal infusions of opioid and/or bupivacaine in refractory nonmalignant pain: a comparison between the epidural and the intrathecal approach with externalized or implanted catheters and infusion pumps. Clin J Pain 1998;14(1):4-16.
Gilmer-Hill HS, Boggan JE, Smith KA, Wagner FC Jr. Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Surg Neurol 1999;51(1):12-5.
Harvey SC, O’Neil MG, Pope CA, Cuddy BG, Duc TA. Continuous intrathecal meperidine via an implantable infusion pump for chronic, nonmalignant pain. Ann Pharmacother 1997;31(11):1306-8.
Hassenbusch SJ. Epidural and subarachnoid administration of opioids for nonmalignant pain: technical issues, current approaches and novel treatments. J Pain Symptom Manage 1996;11(6):357-62.
Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GK. Clinical realities and economic considerations: economics of intrathecal therapy. J Pain Symptom Manage 1997;14(3 Suppl):S36-48.
Hayes SR, Vogelsang J. Opiate receptors and analgesia: an update. J Post Anesth Nurs 1991;6(2):125-8.
Kanoff RB. Intraspinal delivery of opiates by an implantable, programmable pump in patients with chronic, intractable pain of nonmalignant origin. J Am Osteopath Assoc 1994;94(6):487-93.
Koulousakis Kuchta Weber Intrathecal opioid/baclofen combination therapy for chronic intractable pain. In: Raj P, Erdine S, et al, editors. The pain clinic. Bologna, Italy: Monduzzi; 1996. p. 265-9.
Krames ES, Lanning RM. Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage 1993;8(8):539-48.
Kuchta J, Koulousakis A, Weber M, Klug N, Bayarassou A, Theisohn M. Chronic intrathecal application of morphine: distribution of morphine and its metabolites in spinal fluid and serum. In: Raj P, Erdine S, et al, editors. The pain clinic. Bologna, Italy: Monduzzi; 1998. p. 271-5.
Lamer TJ. Treatment of cancer-related pain: when orally administered medications fail. Mayo Clin Proc 1994;69(5):473-80.
Levy R. Implanted drug delivery systems for control of chronic pain. Chapter 19 of Neurosurgical Management of Pain. New York: Springer-Verlag; 1997.
Maron J, Loeser JD. Spinal opioid infusions in the treatment of chronic pain of nonmalignant origin. Clin J Pain 1996;12(3):174-9.
Nitescu P, Dahm P, Appelgren L, Curelaru I. Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treat- ment of “refractory” nonmalignant pain. Clin J Pain 1998;14(1):17-28.
Ochs G. Die spinale Opiat-Analgesie in der Behandlung chronischer Schmerzen. Nervenheilkunde 1998;17:173-5.
Onofrio BM, Yaksh TL. Long-term pain relief produced by intrathecal morphine infusion in 53 patients. J Neurosurg 1990;72(2):200-9.
Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Phar- macol Ther 1990;47(1):12-9.
Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996;11(2):71-80.
Paice JA, Winkelmüller W, Burchiel K, Racz GB, Prager JP. Clinical realities and economic considerations: efficacy of intrathecal pain therapy. J Pain Symptom Manage 1997;14(3 Suppl):S14-26.
Portenoy RK. Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med Singapore 1994;23(2):160-70.
Säwe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 1986;11(2):87-106.
Wahlström A, Winblad B, Bixo M, Rane A. Human brain metabolism of morphine and naloxone. Pain 1988;35(2):121-7.
Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996;85(3):458-67.
Winkelmüller W, Burchiel K, van Buyten JP. Intrathecal opiod therapy for pain: efficacy and outcomes. Neuromodulation 1999;2(2):67-76.
Willis KD, Doleys DM. The effects of long-term intraspinal infusion therapy with noncancer pain patients: evaluation of patient, significant other, and clinic staff appraisals. Neuromodulation 1999;2(4):241-53.
Wolff T, Samuelsson H, Hedner T. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Pain 1996;68(2-3):209-16.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2009 Athanasios Kolousakis, J. Kuchta, A. Bayarassou, V. Sturn
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
